Company intelligence / Profile preview

Avexa Limited

Hawthorn East, Melbourne, Victoria, Australiaavexa.com ↗

Ownership: Private
Employees: ~2
Development stage: Phase 3

Overview

Avexa's lead drug apricitabine (ATC) showed promising Phase III safety and efficacy results for treatment-experienced HIV patients, but development was halted in 2010 after failing to attract a licensing partner. The company also had antibacterial programs and an integrase inhibitor program for HIV.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

apricitabine

Discontinued

Partnerships

Shire Pharmaceuticals (licensing agreement for apricitabine)Valevia (antibacterial portfolio licensed in 2010)

Beyond the preview

Go deeper on Avexa Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avexa Limited.

Explore the full profile